CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

ClinicalTrials.gov ID: NCT00044018

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00044018. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of the study is to select the dose regimen of CDC-501 that provides the most promising evidence of efficacy.

Study identification

NCT ID: NCT00044018
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Celgene; Industry
Enrollment: 102 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

CDC-501 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 1, 2002 (Actual)
Primary completion: Dec 1, 2004 (Actual)
Completion: Feb 15, 2007 (Actual)
Last update posted: Nov 12, 2019

2002 – 2007

United States locations

U.S. sites: 4
U.S. states: 4
U.S. cities: 4

Facility	City	State	ZIP	Site status
H Lee Moffit Cancer Center	Tampa	Florida	33612	—
Dana-Farber Cancer Institute	Boston	Massachusetts	02115	—
Mayo Clinic	Rochester	Minnesota	55902	—
St Vincent's Cancer Center	New York	New York	10011	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00044018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2019 · Synced Nov 15, 2026